Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.
The 3435C-->T polymorphism at the multidrug resistance gene 1 (MDR1) was examined in 74 patients with human immunodeficiency virus who initiated atazanavir therapy. The MDR1 genotype distribution at position 3435 was 28% CC, 45% CT, and 27% TT. Plasma levels of atazanavir were significantly higher in patients with genotype CC than in those with CT or TT, and bilirubin levels correlated with atazanavir concentrations.
Rodríguez Nóvoa
Sonia
S
Clinical Pharmacokinetic Unit, Hospital Carlos III, Madrid, Spain.
Barreiro
Pablo
P
Rendón
Ana
A
Barrios
Ana
A
Corral
Angélica
A
Jiménez-Nacher
Inmaculada
I
González-Lahoz
Juan
J
Soriano
Vincent
V
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D018791:CD4 Lymphocyte Count; D005260:Female; D019450:Genes, MDR / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D006932:Hyperbilirubinemia / Q000097:blood / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D009842:Oligopeptides / Q000009:adverse effects* / Q000097:blood* / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D011725:Pyridines / Q000009:adverse effects* / Q000097:blood* / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D012307:Risk Factors; D019562:Viral Load
D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D012367:RNA, Viral; D000069446:Atazanavir Sulfate